- Home
- GSIW vs AEON Comparison
GSIW vs AEON Comparison
Compare GSIW & AEON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GSIW | AEON |
|---|---|---|
| Founded | 2016 | N/A |
| Country | Hong Kong | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.6M | 13.0M |
| IPO Year | 2022 | 2021 |
Fundamental Metrics
Financial Performance| Metric | GSIW | AEON |
|---|---|---|
| Price | $10.33 | $0.17 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $1.82 |
| AVG Volume (30 Days) | 5.8K | ★ 672.2K |
| Earning Date | 08-04-2026 | 11-17-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.05 | $0.18 |
| 52 Week High | $38.55 | $1.45 |
Technical Indicators
Market Signals| Indicator | GSIW | AEON |
|---|---|---|
| Relative Strength Index (RSI) | 44.00 | 30.43 |
| Support Level | $9.39 | N/A |
| Resistance Level | $12.16 | $0.33 |
| Average True Range (ATR) | 0.58 | 0.03 |
| MACD | 0.26 | -0.01 |
| Stochastic Oscillator | 43.12 | 17.22 |
Price Performance
Historical ComparisonAbout GSIW Garden Stage Limited
Garden Stage Ltd, through its subsidiaries is a Hong Kong-based financial services provider principally engaged in the provision of placing and underwriting services; securities dealing and brokerage services; asset management services; investment advisory services; due diligence services; and introduction and referral services. The company operates in a single segment and derives all of its revenue from Hong Kong.
About AEON AEON Biopharma Inc.
AEON Biopharma Inc is a biopharmaceutical company focused on the development of ABP-450 (prabotulinumtoxinA), a biosimilar to Botox (onabotulinumtoxinA), for therapeutic indications. The company is advancing ABP-450 through the biosimilar regulatory pathway and holds development and commercialization rights across multiple international markets.